Trials / Withdrawn
WithdrawnNCT00358683
A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
Open Label Long Term Clinical Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87055 Study.
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The primary aim of this study is allow the patients suffering from Crohn's disease , who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with certolizumab pegol until the drug is available for the Crohn's disease indication in Greece.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certolizumab pegol |
Timeline
- Start date
- 2007-11-01
- First posted
- 2006-08-01
- Last updated
- 2012-05-28
Source: ClinicalTrials.gov record NCT00358683. Inclusion in this directory is not an endorsement.